Pancreatic ductal adenocarcinoma (PDA) remains a highly lethal disease; new therapeutic modalities are urgently needed. A number of immunotherapies tested in preclinical models have shown promise. Early-phase clinical trials have demonstrated evidence of immune activation that in some cases correlates with clinical response. Moreover, recent evidence delineates the intricate role of inflammation in PDA, even at its earliest stages. Pancreatic ductal adenocarcinoma is thus ripe for immunotherapy; however, significant challenges remain before success can be realized. Future studies will need to focus on the discovery of novel PDA antigens and the identification of the multiple immune suppressive pathways within the PDA tumor microenvironment that inhibit an effective PDA-targeted immune response. Technologies are now available to rapidly advance discovery. Rapid translation of new discoveries into scientifically driven clinical trials testing combinations of immune agents will likely continue to shift the procarcinogenic tumor environment toward the most potent anticancer response.
P ancreatic ductal adenocarcinoma (PDA) is the fourth leading cause of cancer-related deaths in the United States with an estimated 43,920 new cases and 37,390 deaths in 2012. 1 Despite dramatic improvement in mortality after surgical intervention and discovery of new chemotherapy regimens, there has been minimal improvement in disease-free and overall survival over the past 30 years. As the field of cancer immunology has grown, a deeper understanding of the immune system's recognition of tumor cells and their antigens has translated into exciting new treatments for a variety of solid tumors including PDA.
Emerging evidence supports a critical role for the immune system in PDA tumor development, progression, and eradication. Clark et al 2 developed a preclinical immune competent mouse model genetically engineered to develop PDA via a point mutation in one Kras allele. This Kras mutation initiates pancreatic intraepithelial neoplasia (PanIN), which eventually progresses to PDA, and recapitulates the stromal and inflammatory cell milieu found in human PDA development. 2, 3 Evaluation of these murine PDA and PanINs demonstrated that 50% of the tumor was composed of leukocytes, particularly immunosuppressive cells, including tumor-associated macrophages, myeloidderived suppressor cells, and regulatory T cells (Tregs), along with a very small percentage of effector T cells. The authors therefore implicated immunosuppressive cells in early PDA tumorigenesis and a possible role in facilitating disease progression. 2 Other preclinical studies have recently demonstrated the role of chronic inflammation in PDA carcinogenesis. For example, the expression of specific cancer test genes observed in human chronic pancreatitis specimens correlates with expression by their corresponding human PDA tumors. 4 As another example, Guerra et al 5, 6 found that Kras-mutated mice required a second signal in the form of chronic pancreatitis to develop PDA, suggesting that PDA stems from a combination of genetic and nongenetic (e.g., chronic pancreatitis) events. 5, 6 In addition, infiltrating neutrophils have been shown to contribute to PDA tumorigenesis and immune system evasion in PDA preclinical models by activating angiogenesis in the earliest stages of PDA. 7Y9 Furthermore, Esposito et al 10 showed that mononuclear inflammatory cells of the innate immune response are recruited to PDAs and may influence the metastatic capacity of the cancer cells. Finally, cyclooxygenase-2 expression is elevated in human PDA and PanIN lesions and increases with increasing PanIN severity when compared to normal pancreas and chronic pancreatitis. 11, 12 Although PDA was originally thought to be poorly immunogenic, recent data have challenged this presumption. First, a high incidence of tumor-specific T lymphocytes is seen in bone marrows of patients with PDA. 13 Second, Fukunaga et al 14 analyzed 80 surgically resected PDA tumors looking specifically for CD4 + T cells, CD8 + T cells, and dendritic cells within the tumor. They reported that higher levels of CD4 + and CD8 + tumor-infiltrating lymphocytes in PDAs were associated with longer overall survival after surgical resection. The presence of both CD4 + and CD8 + tumor-infiltrating lymphocytes was an independent favorable prognostic factor in a multivariate analysis. 14 However, still not known is whether these T cells are PDA specific.
These data, together with results from early immunotherapy clinical trials (discussed below), support the hypothesis that PDA is able to elicit an antitumor immune response. However, this is the exception rather than the rule because there also exist a variety of mechanisms that naturally suppress this response. Importantly, many of these mechanisms likely also support tumor growth and progression. The question is no longer whether or not immunotherapy will improve PDA outcomes, but how do we improve the immune system's anti-PDA immune response and limit the tumor's ability to evade immune system detection? This review will discuss our current understanding of tumor antigens, vaccines that are capable of delivering these antigens to induce a PDA-specific immune response, and the mechanisms within the tumor microenvironment that inhibit effective immunity. In addition, preclinical and clinical studies testing combinatorial immunotherapy approaches that bypass mechanisms of immune tolerance to activate the most potent antitumor immune response will be summarized.
TUMOR ANTIGENS AND IMMUNE TOLERANCE
Cancer cells are derived from their normal counterparts after undergoing genetic alterations resulting in their malignant phenotype. These genetic alterations lead to the expression of tumorassociated antigens (TAA), which are misfolded altered proteins expressed by cancer cells. Tumor-associated antigens are presented by major histocompatibility complex (MHC) molecules (human leukocyte antigen [HLA] in humans) to effector T cells. These T cells contain unique T-cell receptors, which recognize specific antigen epitopes bound to MHC molecules. This interaction is known as ''signal 1.'' Signal 1 alone is insufficient for appropriate T-cell activation and results in T-cell anergy or apoptosis, allowing the tumor to evade immune system detection. The concomitant binding of costimulatory molecules, such as B7-1 and CD28, on antigenpresenting cell (APC) and T-cell surfaces, respectively, results in ''signal 2,'' a critical component in T-cell activation (Fig. 1A) .
Most tumor cells lack the necessary surface molecules, that is, B7-1 (CD80) and B7-2 (CD86), to complete 15 signal 2. Professional APCs, for example, dendritic cells (DCs), are more efficient T-cell activators. Intracellular processing mechanisms unique to DCs enable them to efficiently process tumor antigens and present them on both MHC I and MHC II surface molecules resulting in tumor-specific CD8 + and CD4 + T-cell activation, respectively. Mature DCs constitutively express costimulatory molecules in close proximity to MHC complexes. 16 Examples of members of the currently known costimulatory families are shown in Figure 1B .
Immunotherapy of cancer aims to take advantage of the immune system's natural ability to recognize and react against new antigensVin the case of cancer, TAAs. However, tumor cells use various mechanisms to evade immune system detection. Inflammatory signals, that is, interferon gamma (IFN-F), transforming growth factor A (TGF-A), and interleukin 10 (IL-10), play critical roles in both tumor eradication and development ( Fig. 1A ). 17 Cell surface molecules such as cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed cell death (PD)-1, PD-L1 (B7-H1), and PD-L2 (B7-DC) are examples of immune checkpoint signaling pathways, which down-regulate T-cell activation. 18 Other families of checkpoint inhibitors are shown in Figure 1B .
Tumor cells, stromal cells, and immune cells within the tumor microenvironment all produce factors that suppress TAAspecific T-cell responses. Transforming growth factor A and the TGF-A receptor interaction results in nuclear translocation of the SMAD4/DPC4 complex. 19 The SMAD/DPC4 complex has been shown to suppress tumor growth and is down-regulated in more than 50% of advanced PDAs. 20 Transforming growth factor A directly inhibits T-cell proliferation and suppresses CD8 + Tcell activity via its interactions with SMAD4/DPC4 intracellular protein complex. 19 Moreover, TGF-A up-regulates FoxP3 expression, a marker for CD4 + CD25 + Tregs, which play an integral part in the tumor's ability to evade the immune system. 19 Interleukin 10, produced by Tregs and other immune cells, promotes immune tolerance by directly inhibiting APCs and helper T cell 1 (T H 1) differentiation and proliferation. 21 Analysis of human pancreatic cancer cells after surgical resection demonstrated tumor-derived TGF-A and IL-10 acting in conjunction to promote a T H 2 cell response and inhibit T H 1 cell differentiation and proliferation. 22 T H 2 predominant immune responses are associated with poor protection against malignant tumors and reduced survival in patients with pancreatic cancer when compared with a T H 1 response. 23, 24 This is most likely due to DCs' inability to activate CTLs in the presence of IL-10 and IL-10's ability to act directly on tumor cells and down-regulate HLA class I expression. 21 Cytotoxic T-lymphocyte antigen 4 is expressed on the activated T-cell surface and competes with CD28 to bind B7-1. This interaction turns off the activated T cells by inhibiting B7.1's intracellular signaling cascade. The CTLA-4 B7.1 interaction limits the immune system's activation response to both foreign and selfantigens. Cytotoxic T-lymphocyte antigen 4 knockout mice display severe autoimmune disease and have shortened lifespans. 18 Although these immunologic checkpoints are important in maintaining self-tolerance, tumor cells use them to turn off the antitumor immune response.
B7-H1 (PD-L1), and B7-DC (PD-L2) are cell surface ligands expressed by many tumor cells, DCs, activated T cells, B cells, and macrophages. They bind to their shared receptor, PD-1, on activated CD4 + and CD8 + T cells. The PD-L1 or PD-L2 and PD-1 interaction down-regulates activated CD4 + and CD8 + T cells resulting in cell cycle arrest. 25 This tumor-specific immunologic checkpoint is yet another mechanism used by tumor cells for immune evasion.
The tumor microenvironment uses various other mechanisms and factors such as vascular endothelial growth factor, IL-6, and cyclooxygenase to impede DC differentiation and maturation. 2, 16 Moreover, DC-activating cytokines such as granulocyte macrophage colony-stimulating factor (GM-CSF) and IL-4 are decreased in the tumor microenvironment. 16 Stromal cells also secrete cytokines, chemokines, and other tumor-promoting factors that inhibit effective tumor killing. 17 Thus, the combination of stromal cells, DCs, endothelial cells, macrophages, and tumor cells within the tumor microenvironment secrete a combination of cytokines and cellular signals that ultimately determine whether a protumor or antitumor immune response is triggered. As discussed below, immunotherapies aim to tip the balance in favor of an antitumor immune response.
TUMOR-ASSOCIATED ANTIGEN IDENTIFICATION AND ANTIGEN PRESENTATION
The identification of PDA TAAs remains critical to the development of more effective vaccine therapy and the assessment of tumor-specific T-cell responses. For many years, PDA vaccines targeted a few known proteins that were either the products of oncogenes (mutated Kras) or differentially expressed glycoproteins such as MUC1 and CEA. 26 The recent developments in genetics and proteomics have accelerated progress in PDA antigen identification ( Fig. 2 ). Differential gene expression analyses enable identification of highly expressed genes in PDA cells when compared with nonneoplastic cells. As an example, using serial analysis of gene expression, Argani et al 27 identified mesothelin as being overexpressed in most (close to 100%) PDAs. A follow-up study used immunized lymphocytes from patients with PDA treated with a GM-CSFYsecreting vaccine (GVAX) to screen mesothelin peptides and demonstrated an increase in postvaccine T cells specific for mesothelin in patients who demonstrated prolonged disease-free survival (DFS). 28 Mesothelin encompasses many of the principles necessary for an optimal tumor antigen in that it has a very low expression profile in normal cells, is highly expressed in PDA cells, and is possibly involved in cancer progression and metastasis 17 (Fig. 3 ). Antimesothelin antibodies have been used in early-phase clinical trials in patients with PDA, mesothelioma, and ovarian cancer with limited clinical efficacy. 29 However, a live attenuated Listeria monocytogenes recombinant bacterial vaccine expressing mesothelin was administered to patients with metastatic PDA with more than 37% of patients living longer than 15 months. 30 A phase 2 randomized controlled multicenter trial is currently evaluating the combination of L.
monocytogenes expressing mesothelin as a boost after priming with pancreatic GVAX in adults with metastatic PDA (discussed later in this paper).
In recent years, proteomic-based approaches such as serological analysis of recombinant complementary DNA expression libraries, serological proteome analysis, and protein microarray technology have all been used as an alternative approach to identify tumor antigens. Annexin A2 was recently identified as a PDA antigen, using human sera to screen the proteins expressed by the PDA GVAX, which served as the proteome. Subsequently, pretreatment and posttreatment sera were analyzed from 60 patients treated with GVAX and FIGURE 1. A, Tumor-associated antigens are expressed as small peptide fragments on HLA molecules and presented to T cells for recognition and activation and is referred to as T-cell signal 1. However, tumor cells cannot effectively activate T cells alone because they do not express the costimulatory molecules such as B7.1 and B7.2, which provide signal 2. Vaccines are designed to deliver TAAs to antigen-presenting cells, which naturally up-regulate both signal 1 and signal 2. Dendritic cells are the most efficient antigen-presenting cells owing to their ability to readily process tumor antigen and present them on both MHC I and II surface molecules, which then bind to T-cell receptors on both CD4 + and CD8 + T cells. Dendritic cells also up-regulate B7-1/B7-2 expression (signal 2) for efficient T-cell activation.
Members of immune regulatory cell surface receptors on T cells such as CTLA-4 turn off activated T cells by competing with activating receptors (signal 2) for the same ligand, allowing the tumor to evade immune recognition. Cytokines produced by T cells mediate both activating and inhibitory immune responses. B, Examples of different family members of both costimulatory and inhibitory signals on antigen-presenting cells that interact with T cells. TCR indicates T-cell receptor; MHC, major histocompatibility complex.
demonstrated a posttreatment induction of annexin A2 antibodies in most of the patients with prolonged DFS. 31 This suggested that antibody responses might be inhibiting annexin A2Ymediated tumor progression. Preclinical studies demonstrated that annexin A2 plays a critical role in pancreatic cancer invasion and metastasis, making it unlikely that annexin A2 FIGURE 2. Methods of tumor antigen identification. Differential gene analysis, exome sequencing, and proteomics are 3 different methods of identifying tumor TAAs in PDA. Immunoassays conducted on T cells from vaccinated patients with PDA determine the presence of antigen-specific cytotoxic CD8 + T cells. These antigens can then be used to develop more potent antigen-specific immunotherapies. expression will be lost during cancer progression. 31 Moreover, annexin A2-directed therapy prevented tumor metastases in 2 mouse models of PDA, suggesting a critical role for annexin A2 in PDA metastatic activity. Antiannexin antibodies and vaccines are currently in development for future clinical testing. 32 Exome sequencing is a type of high-throughput dideoxy sequencing analysis that specifically focuses on the coding portion of the genome and is capable of identifying most types of coding genetic alterations in human cancer. 33 Jones et al 34 analyzed 24 pancreatic cancers and found that they contain an average of 63 genetic alterations. These alterations identified a core set of 12 cellular signaling pathways including Kras signaling, TGF-A signaling, and hedgehog signaling pathways, which were modified in 67% to 100% of the tumors. 34 More and more PDA tumors have been sequenced using exome sequencing. This type of high-output and efficient gene analysis provides the opportunity to move from generic vaccines to patient-specific vaccines. It is now possible to quickly sequence individual patient tumors and identify patient-specific mutations that may serve as unique vaccine targets. These new mutation-derived TAAs are likely to be critical to that particular tumor's growth and differentiation, and also a relatively new change in the tumor microenvironment, thereby decreasing the likelihood of immune tolerance to these unique antigens. One study has already shown that specific mutation identification using exome sequencing can lead to the discovery of novel and unique epitopes with higher affinity to HLA complexes, thereby enhancing antigen presentation. 35 Thus, future pancreatic cancer vaccine therapy should feasibly be tailored to the individual patient based on their own tumor characteristics.
VACCINE THERAPY
The most potent vaccine therapy potentiates antigen presentation by DCs activating pathogen-specific effector and memory T cells. Cancer vaccines were first approved for hepatoma and cervical cancer prevention. More recently, the first vaccine (Provenge, Sipuleucel-T) was approved for the treatment of prostate cancer. 36 
Antigen-Specific Vaccines
Antigen-specific vaccines target known tumor antigens, thereby eliciting a tumor-specific immune response. Peptide or protein vaccines use identified immunodominant tumor epitopes to stimulate T-cell antitumor responses. In PDA, the natural starting point for these vaccines became tumor markers such as carcinoembryonic antigen (CEA) and MUC-1, as well as mutated proteins that play a prominent role in PDA such as Ras and telomerase. 37 The advantages of peptide vaccines include ease of manufacturing and administration, but they are also poorly immunogenic and less able to create immunological memory. 38 The first clinically tested PDA vaccine was a mutant Ras peptide vaccine designed to stimulate an antimutant Ras response. Of the 5 patients with PDA in this trial, two lived more than 8 months, and immunologic analysis demonstrated the presence of tumor and Ras mutationYspecific CD4 + and CD8 + T cells in both of these patients. 39, 40 However, follow-up studies failed to show clinically significant immunity to peptidedelivered Kras.
Evidence suggested that the treatment failure of these early vaccines was due to the immune system's inability to respond appropriately to these antigens. 41 This led to the discovery that local cytokines were crucial in eliciting a proper immune response and that GM-CSF was found to be most effective at stimulating the activation of both CD4 + and CD8 + T cells in murine tumor models. 41, 42 Subsequently, peptide vaccination was administered in combination with GM-CSF, eliciting more effective DC activation and antigen presentation. A second mutated ras peptide vaccine clinical trial was conducted, where 48 patients with histologically confirmed PDA received mutant ras peptide vaccine, this time in combination with intradermal GM-CSF. More than 50% of patients demonstrated a tumorspecific immune response associated with their Ras-mutant vaccine. Moreover, these patients demonstrated a statistically significant improved median overall survival versus their nonresponding counterparts (148 vs 61 days, P = 0.0002; Table 1 ). 43 Another early-phase clinical trial used a gastrin-based vaccine in 154 patients with advanced-stage PDA. This multiinstitution double-blinded placebo-controlled trial demonstrated a nearly 2-fold increase in the median overall survival in the treatment versus the placebo group (151 vs 82 days, respectively, P = 0.03). 45 Antigastrin immune responses were noted in 73.8% of the patients and correlated with longer overall median survival versus nonresponders and placebo (176 vs 63 vs 83 days, respectively; P = 0.003). 45 Telomerase, which is reactivated in more than 85% of PDA cells, has also been used to develop PDA peptide vaccines. Phase 1 and 2 clinical trials involving patients with locally advanced and metastatic PDA also demonstrated prolonged survival in immune responders versus nonresponders in early-phase clinical trials. 44, 53 These studies were encouraging, demonstrating evidence of immune induction that was associated with survival benefits. However, the very modest survival benefits were likely due to the suboptimal ability of peptide vaccines to adequately activate DCs and induce the most potent immune response. 44 Recombinant vaccines contain bacterial and viral antigen carriers, thereby increasing DC activation and improving antigen presentation. They stimulate the innate immune response while efficiently recruiting and activating DCs. The most common carriers include Bacille Calmette-Guerin, L. monocytogenes, Salmonella, and poxviruses. Clinical trials using CEA and MUC1 recombinant vaccines have shown little efficacy in patients with PDA. However, the failure of this approach was likely due to the lack of immunogenicity of the TAAs that were targeted and to the advanced stage of the PDA in patients in the study. 46 ,54Y56 L. monocytogenesYbased vaccines have been widely studied, given L. monocytogenes's intracellular life cycle and subsequent ability to target MHC class I and II pathways. 57 Additionally, L. monocytogenes is simple to grow, treat, and easily engineered to express antigens, making it an ideal vector for tumor immunotherapy. 57 Genetically engineered L. monocytogenes vaccines carrying tumor antigens have been studied in murine breast and colon cancer models. L. monocytogenes vaccination provided tumor regression and overall survival improvement versus placebo. 58, 59 In a preclinical metastatic colon cancer model, an attenuated L. monocytogenes strain expressing the immunodominant murine colon cancer antigen AH1 was shown to increase overall survival. L. monocytogenes was noted to preferentially infect the liver and promote a peritumoral proinflammatory environment leading to the influx of tumor-specific T cells and IFN-F production. 60 These findings sparked the first human studies using antigen expressing L. monocytogenesY based vaccines.
Patients with a diagnosis of hepatic metastases from mesothelioma, ovarian cancer, nonYsmall cell lung cancer, and PDA were administered a live attenuated Listeria strain expressing mesothelin, a cell surface molecule overexpressed by these tumors. The vaccine was well tolerated with minimal adverse effects. 30 Thirty-seven percent of the patients survived 15 months or more. Half of these patients were those with metastatic PDA, and immunologic analysis revealed listeriolysin O and mesothelin-specific T-cell responses. 30 Viral vectors have also been modified to express TAAs such as prostate-specific antigen, and human papillomavirus antigens. A poxvirus PDA vaccine expressing both MUC-1 and CEA combined with GM-CSF called PANVAC-V has also been developed. A phase 1 trial involving patients with advanced treatmentYrefractory PDA reported a median overall survival of 6.3 months. 46 Immunologic analysis revealed a MUC-1Y or CEA-specific T-cell response in 62.5% of patients and was associated with a significant survival advantage over nonresponders (15.1 vs 3.9 months, respectively, P = 0.002). 46 A phase 3 randomized controlled clinical trial of 255 patients with metastatic pancreatic cancer was conducted, where PANVAC-V was compared with standard gemcitabine therapy; and regrettably, the vaccine failed to demonstrate an improvement in overall survival. 56 As discussed earlier, DCs play a critical role in creating an efficient antitumor immune response. Dendritic cell vaccines attempt to exploit these characteristics by isolating DCs and loading them with tumor-associated antigens or tumor mRNA while in culture and subsequently reinfusing them in patients. 61 Dendritic cell vaccine therapy has been mostly studied in prostate cancer, breast cancer, melanoma, and renal cell cancer, where it has been generally well tolerated but with underwhelming clinical efficacy. 17 Twelve patients with surgically resected pancreatic and biliary cancer were treated with MUC-1Yloaded DC vaccine in an early-phase clinical trial. Thirtythree percent of these patients were alive 4 years after treatment although immunological analysis did not demonstrate elevated anti-MUC1 antibodies. 47 In a separate clinical trial, DC vaccine therapy combined with standard gemcitabine in patients with inoperable PDA refractory to standard treatment failed to demonstrate a statistically significant survival advantage. 62 The reason for this failure could be due to the lack of immunogenicity of the TAA that was targeted, to the combination with gemcitabine, which can induce lymphopenia and dampen the immune system's ability to respond, or to the advanced stage of the patients treated.
Unfortunately, we are often unable to ascertain which specific tumor antigen will lead to the most robust immune response in each particular patient. The ideal antigen will not be susceptible to preexisting tolerance, will be critical to the tumor's malignant phenotype and will be expressed solely by the tumor. 17 Given the tumor's adaptive ability and everchanging genome, it is unlikely that a single antigen will fulfill all of these criteria.
Whole-Cell Vaccines
Whole-cell vaccines avoid the need for antigen specification because they include irradiated whole tumor cells. These tumor cells are transduced with GM-CSF genes and more efficiently prime the immune system by enhancing antigen presentation by DCs. Multiple tumor antigens can then be processed from the irradiated tumor cells in the presence of these activated DCs.
The first clinical application of GM-CSFYtransduced whole-cell vaccines was attempted in patients with late-stage renal cell carcinoma. The vaccine was well tolerated at all doses with minimal clinical adverse effects. Delayed-type hypersensitivity reactions were noted in patients receiving the GM-CSF autologous vaccine and correlated with their clinical response. 63 Autologous whole-cell vaccines have subsequently been tested in melanoma, prostate, and nonYsmall cell lung cancer.
Unfortunately, the processing and development of autologous vaccines is not feasible for all cancers, including PDA. An alternative approach is the use of allogeneic whole-cell tumor vaccines. The potential drawback when compared with autologous vaccines is that patients are no longer being vaccinated against their own specific tumor antigens. Evidence suggests, however, that antigen presentation by DCs is host derived; and therefore, the vaccine cell's sole role is to present antigens. 41 Additionally, of the tumor antigens we have identified in melanoma, more than 50% are shared among all tumor cell lines, making allogeneic vaccination a reasonable approach. 41 Allogeneic GM-CSF vaccine therapy, called GVAX, has been tested in a variety of early-phase clinical trials. For the most part, it has been well tolerated with minimal adverse effects. 64, 65 The first phase 1 study of pancreatic GVAX was performed on 14 patients with stage 2 or 3 surgically resected PDA. The vaccine was administered in 3 escalating doses, the first one being 8 weeks after surgical resection. Patients then received standard adjuvant chemoradiation for 6 months followed by 3 additional monthly vaccinations. Postvaccination delayed-type hypersensitivity responses to autologous tumor cells were noted in 3 of the 14 patients, all three of which are alive more than 12 years after their diagnosis. 48 Mesothelin has been considered as a PDA tumor antigen because it is up-regulated in most pancreatic tumor cells. Immunologic analysis of the phase 1 pancreatic GVAX trial demonstrated induction of CD8 + T cells to multiple HLA-A2Y, HLA-A3Y, and HLA-A24Yrestricted mesothelin epitopes in the 3 patients experiencing delayed-type hypersensitivity responses. 28 None of the tumor cells used in GVAX were shown to express HLA-A2, HLA-A3, or HLA-A24, thus providing the first clear-cut evidence that tumor-specific CD8 + T cells can be generated by an immunotherapy approach designed to recruit APCs to the vaccination site. 28 A phase 2 GVAX study was subsequently conducted in 60 patients with surgically resected PDA. Again, the patients received their first vaccine 8 weeks after surgical resection followed by standard chemoradiation. If patients were disease-free at that point, they then received 3 additional monthly vaccines. In contrast to the phase 1 study, the patients in this phase 2 trial received an additional and final fifth vaccine 6 months after their fourth vaccine. The median DFS and overall survival were 17.3 months (95% CI, 14.6Y22.8) and 24.8 months (95% CI, 21.2Y31.6), respectively. 51 The vaccine was well tolerated with minimal adverse effects. Moreover, immunologic analysis revealed mesothelin-specific CD8 + T cells that correlated with prolonged DFS. 51 A second phase 2 clinical trial looked at the combination of GVAX therapy with immune-modulating doses of cyclophosphamide (Cy). It was also the first study where GVAX therapy was used to treat patients with metastatic PDA. Eligible patients were those with stage 4 PDA who had failed gemcitabine therapy. Fifty patients were divided without randomization into 2 arms: 30 patients received GVAX alone and 20 patients received intravenous cyclophosphamide 1 day before GVAX therapy. The median survival was 2.3 months in the GVAX alone versus 4.7 months in the GVAX plus Cy cohort. 49 Although not statistically significant, the presence of higheravidity mesothelin-specific T cells showed a strong trend toward prolonged progression-free survival. 49 The Cy and GVAX combination was well tolerated with minimal adverse effects. The authors concluded that vaccine therapy in combination with immune-modulating doses of cyclophosphamide is safe, feasible, and acceptable treatment for patients who have progressed on first-line chemotherapy regimens. 49 Our group is currently conducting a phase 2 study to assess how long after initial vaccination patients with PDA should continue receiving boosting vaccinations. Eligible patients for this study include disease-free survivors from the aforementioned phase 1 and phase 2 GVAX trials and vaccine-naive patients who have received 4 primary monthly vaccinations. The boosting vaccination protocol calls for vaccination every 6 months as long as the patient remains disease-free.
Despite the encouraging safety and survival data from these phase 1 and phase 2 trials, tumor tolerance continues to limit vaccine therapy. Animal studies suggest that Cy does not have a durable effect in depleting Tregs, but repetitive administration of metronomic Cy may lead to durable Treg inhibition. 66 An ongoing randomized controlled clinical trial is now testing GVAX in combination with Cy, including metronomic Cy, in patients with resectable PDA in the neoadjuvant and adjuvant setting. Eligible patients are randomized into one of 3 arms: GVAX alone, GVAX in combination with Cy given 1 day before each vaccination, or GVAX in combination with repetitive administration of metronomic Cy. Primary end points include the assessment of the immune cell infiltrates, particularly Tregs, CD4 + and CD8 + effector T cells in the resected tumors after the neoadjuvant vaccination, and the assessment of the changes in the number and function of peripheral mesothelin-specific CD8 + T cells. Participants receive their first vaccination 2 weeks before undergoing pancreatic resection (the Whipple procedure) and a second vaccination in 6 to 10 weeks after surgical resection followed by standard adjuvant chemoradiation. If patients remain disease-free 1 to 2 months after standard adjuvant therapy, they receive the vaccine once every 28 days for a total of 6 vaccinations.
Administering the vaccine in the neoadjuvant setting for the first time has given insight into the tumor's ability to evade the immune system and suppress vaccine therapy. Immunohistochemical staining of the resected tumors has revealed peritumoral and intratumoral lymphoid aggregates for the first time. Moreover, PD-1Y and B7-H1Ypositive immune cells are abundantly present within these aggregates, suggesting that a combination of PD-1 and B7-H1 blockade may further enhance the antitumor effect of GVAX therapy (unpublished data).
More recently, HyperAcute vaccines, which are allogeneic whole-cell vaccines composed of irradiated cancer cells that have been genetically modified to add >(1,3)-Galactosyl (>Gal) residues to their cell-surface have been used in early-phase clinical trials with promising results. Human cells lack a key enzyme in a common >Gal epitope pathway. Chronic stimulus from gut flora leads to high levels of circulating anti->Gal antibodies. 67 The complement-mediated destruction of >Gallabeled tumor cells results in an enhanced antitumor immune response targeting tumor-associated antigens. A HyperAcute-Pancreas vaccine phase 2 clinical trial of patients with previously resected PDA has been conducted. Hardacre et al 50 reported 90% (18/20) overall survival for patients with approximately 1 year of follow-up. The median DFS had not been reached, but the data suggested a pending significant increase in the median DFS compared with historical controls. 50 Moreover, they reported no significant grade 3 or 4 toxicities. 50 A phase 3 clinical trial is currently being performed.
IMMUNE-MODULATING AGENTS AND COMBINATIONS UNDER DEVELOPMENT FOR PDA
Pancreatic cancer immunotherapy will benefit greatly from PDA-specific tumor antigen identification, but tumor cells still have the capability of using immune checkpoints to evade detection. Cytotoxic T-lymphocyte antigen-4 and PD-1 are well characterized as inducing T-cell apoptosis and anergy when bound to their ligands. Moreover, PD-1 and B7-H1 are highly expressed in peritumoral lymphoid aggregates seen with GVAX therapy, suggesting that this immunologic checkpoint is used to evade antitumor immune response. Single-agent anti-PD1 and anti-CTLA4 therapy has evoked promising results but is most likely insufficient individual treatment regimens for PDA. Mesothelin-specific CD8 + T-cell responses are up-regulated when GVAX is administered in combination with anti-PD1 antibodies versus GVAX alone in murine models (unpublished data). Moreover, the combination of GVAX therapy and anti-PD1 has demonstrated a survival advantage in preclinical metastatic pancreatic cancer models (unpublished data).
Anti-CTLA-4 monoclonal antibody therapy has produced durable tumor regression in murine melanoma models and early-phase clinical trials in patients with advanced melanoma. 18 ,68Y70 Despite these promising results, anti-CTLA-4 therapy is associated with a nearly 30% incidence of grade III/ IV autoimmune toxicity. 70 These adverse effects include colitis and encephalitis but also correlated positively with clinical response. 70 In an early-phase clinical trial of 27 patients with locally advanced or metastatic pancreatic cancer, single-agent ipilimumab, a human anti-CTLA-4 monoclonal antibody, did not have any responders, but one subject did experience a significantly delayed response. 71 As discussed earlier, this was predicted from preclinical models that support combinations of immune modulators with vaccine as being more effective than single-agent immune modulators administered alone.
The combination of vaccine therapy and immune checkpoint blockade is currently being tested in early-phase clinical trials. Le et al 52 conducted a phase 1b trial where 30 subjects with previously treated locally advanced or metastatic PDA were randomized to one of 2 arms: ipilimumab (IPI) alone or IPI in combination with GVAX. The median overall survival was 3.3 months in IPI alone versus 5.5 months in IPI plus GVAX (P = 0.12). Twelve-month overall survival was 7% versus 27% in the IPI group versus IPI plus GVAX group, respectively. 52 Immune-related adverse effect profiles were similar and were associated with increased overall survival in both arms. 52 Although underpowered, this study suggests a possible role for combinatorial immunotherapy in advanced PDA.
The antitumor immune response is determined within the tumor microenvironment. It is here where the complex interactions between tumor cells and the adjacent immune cell network dictate tumor tolerance or eradication. Multiple reports have documented the presence of immunosuppressive cells at the early points of tumor development including Tregs, myeloidderived suppressor cells, and tumor-associated macrophages. 72 This has led to extensive efforts to modify the tumor microenvironment in a manner that limits its immunosuppressive capabilities.
Beatty et al 73 used an agonist CD40 antibody in a preclinical model to demonstrate that CD40-activated macrophages rapidly infiltrate tumors, become tumoricidal, and facilitate the depletion of tumor stroma in a pancreatic cancer murine model. They also tested the agonist CD40 antibody in combination with gemcitabine in patients who were chemotherapy naive and surgically unresectable. Of the 21 patients who received the antibody, 4 patients had a partial response, another 4 patients had progressive disease, and 11 patients had stable disease. 73 Two patients were excluded from the analysis owing to a cerebrovascular accident and inability to receive posttherapy imaging. 73 The median progression-free survival was 5.6 months and the median overall survival was 7.4 months. 73 Compared to historical controls receiving standard gemcitabine therapy, anti-CD40 therapy revealed promising clinical efficacy in this earlyphase clinical trial.
B7-H1, the ligand for the immune T-cell expressed immune checkpoint PD-1, is expressed on DCs and its expression is up-regulated by certain tumor cells. 25 PD-1 is expressed by tumor associated T cells, including Tregs. The PD-1/ B7-H1 interaction decreases IL-12 production by DCs, and the antitumor immune response is limited. 25 Monoclonal antibodies directed at B7-H1 and PD-1 in murine models have led to increased cytotoxic T-cellYmediated tumor-specific immunity and are currently being investigated as single-agent therapies in early-phase clinical trials. 74 Its adverse effect profile is considerably lower than that seen with ipilimumab. Anti-PD-L1 therapy in patients with treatment-refractory nonYsmall cell lung cancer, melanoma, and renal cell cancer was observed to have an objective response rate of 6% to 17%. 75 Anti-PD1 therapy was noted to have an objective response rate of 20% to 25% in a similar patient population. 76 Both therapies were associated with grade III/IV autoimmune toxicity in 9% to 14% of patients. 75, 76 In addition to expressing PD-1, Tregs have a variety of mechanisms that limit the antitumor immune response. 77 Tumors have been shown to induce rapid expansion of Tregs in both human and murine tumor models, leading to delayed rejection of immunogenic tumors. 78Y80 Although they are generally present in small numbers, Treg presence is elevated in the tumor microenvironment. They inhibit CD4 + and CD8 + T cells through direct cell-to-cell contact and by secreting immune mediators such as IL-10 and TGF-A. 17 Hiraoka et al 81 analyzed 198 PDA tumor specimens along with 84 associated PanIN lesions, comparing tumor T-cell populations with nonneoplastic pancreatic tissue. They reported significantly higher Treg populations in PDA tumors when compared with nonneoplastic inflammation (P G 0.0001). 81 Moreover, a higher Treg prevalence within the PDA tumor specimens was associated with a worse prognosis independent of other survival factors (P G 0.0001). 81 Anti-Treg therapy with monoclonal antibodies targeting Treg molecules such as glucocorticoid-induced tumor necrosis factor and LAG-3 [lymphocyte activation gene 3] are being studied in animal models. 82 Immune modulatory doses of cyclophosphamide suppress Treg populations and augment antitumor immune response in patients with PDA when used in combination with vaccine therapy. 83 
CHEMOTHERAPY AND IMMUNOTHERAPY
Recent reports have demonstrated chemotherapy's ability to augment the antitumor immune response. For example, doxorubicin-induced tumor cell apoptosis increases antigen presentation when compared with mitomycin. 84 Additionally, docetaxel and paclitaxel have been shown to improve GM-CSF vaccine antitumor immunity through its ability to increase DC presence and activation. 85, 86 Moreover, Plate et al 87 demonstrated that patients with PDA undergoing gemcitabine therapy had decreased memory T cells and increased de novo T-cell activation.
Studying the relationship between immunotherapy and chemotherapy demonstrates that the timing and dose of chemotherapy can result in a synergistic combination. Metronomic Cy is immune modulating as opposed to high-dose Cy, which is lympho-depleting and immunosuppressive. 88 Cyclophosphamide increases antitumor immunity by decreasing the number and function of Tregs. 89, 90 Moreover, metronomic Cy contributes to the transformation of CD4 + T cells into T H 1 and T H 17 lymphocytes, thereby increasing effector T-cell population. 91 The dose and timing of Cy in relation to vaccine therapy for optimal immunomodulatory effects remains under investigation. Emens et al 92 reported a phase 1 clinical trial looking at dose ranges of an allogeneic Her-2Ypositive GM-CSFYsecreting tumor vaccine in combination with Cy and doxorubicin in patients with metastatic breast cancer. They concluded that the immunomodulatory activity of low-dose Cy has a narrow therapeutic window, not exceeding 200 mg/m 2 .
THE FUTURE OF VACCINE THERAPY
Although encouraging, results from single-agent immunotherapy clinical trials in patients with PDA have been underwhelming. Most gastrointestinal tumors are immune tolerant and therefore require a combinatorial therapeutic approach, which includes chemotherapy, radiation, surgery, and immunotherapy. As more and more tumor antigens are identified, more specific and potent vaccines will be developed. The ideal vaccine will target multiple antigens that are crucial to the growth and progression of tumors. Incorporating immunologic checkpoint blockade inhibitors will allow for increased T-cell activation and tumoricidal activity. Tumor microenvironment modulators will allow for more efficient DC activation, thereby improving antigen presentation. Optimization of PDA vaccine therapy requires additional studies to understand which agents are most important for PDA. This information will come from a continued focus on scientifically driven clinical trials with access to tissue and from genetically engineered mouse models that recapitulate human disease.
